Policybazaar - Insurance Online

What I learned after reading the PolicyBazaar (PB Fintech) Q1FY25 Earnings Call.

Industry-level

The ability to pass on increased costs to customers is a positive sign of pricing power. However, the reliance on modular products and new designs to absorb price hikes raises some concerns.
Sustainable pricing power should stem from a strong brand, value proposition, and customer loyalty. :point_down:

Pricing

For me, this statement is both encouraging and challenging. On one hand, it demonstrates a strong conviction in the industry’s growth prospects. On the other hand, it raises questions about the specific actions the company is taking to address the identified issues and drive the necessary change.:point_down:

US Market

There is significant room for growth and expansion for players like PB Fintech but it will need to differentiate itself and execute effectively to capitalize on the growth potential.:point_down:

opp

Company-level

The comparison to organizational stages is interesting. Positioning the company in the ‘very early days of growth’ is a bold statement, but it’s backed by the impressive numbers. The decision to overspend by $3 million on capacity building is a strategic move that indicates strong confidence in sustained growth. Can the company maintain this momentum in the coming quarters? That remains to be seen. :point_down:

Company Growth

The company is prioritizing investment in operations over short-term profits. This is a common strategy for companies in the early stages of growth, aiming to build a strong market position and customer base. Whether it can convert growth into sustainable profits, that remains to be seen. :point_down:

PAT

The management’s emphasis on the credit score business as a foundational element for customer acquisition and engagement is a strategic move. If PB Fintech can effectively leverage its credit score business to drive customer acquisition and engagement, it could significantly enhance its long-term growth prospects. :point_down:

Co_Credit Score

Management’s dismissive response to the query about revenue comparison is concerning. As an analyst, I would be skeptical of the management’s claims.The rapid growth in PoSP premiums warrants further investigation.

1 Like

I’m new to valuations and investing. I came across this stock with a P/E ratio of 764(Screenr). From what I’ve learned so far, this seems extremely overvalued. Can a valuation expert help me understand this better?

here it will not be right to look on the basis of PE . Basis of valuation of any company is it’s future cash flow discounted to present time . and market expecting good cash flow and operating leverage with time . Thats why PE is not the right valuation parameter here . Although I am new to investing and not a expert of valuation :smiley: but this is what my understanding says.

Thank you for answering my doubt. Just a follow up question:
PB’s current mcap is 79K and since it’s expected to deliver 600cr in fy25, it’s forward PE comes around 130. Now my doubt is, isn’t 139 a high pe still? Sorry for a newbie question!

@joinjp2003 @amit151190 and others what’s your take on Star Health. They have highest market share in Retail health insurance space and have been churning good PAT with guidance of 3x PAT in next 4 years with doubling of Premium.

How shall we compare the PB fintech with a traditional insurance company like Star Health from the valuation perspective?

Health Insurance sector shall explode in India in coming time (the process has already begun). This is the accumulation stage of the long term story thats still panning out.

Thanks!

Disc: Invested in Star Health and PB fintech

2 Likes

Being an Insurance and Banking analyst, In my views insurance is a cyclical and commoditized business , people look for cheapest insurance policy and many a times they don’t even know the name of their insurer. Most of the insurance companies would be having combined ratio more than 100 and the profits come to them through investment income. In case of commodities like steel and iron during the upcycle it takes time for fresh supply to come in so the price would be high for at least few years, while in insurance the supply can be added immediately by an insurer ready to offer lower price. Overall in my views insurance is a tough business and heard some bad news about Star Health in Gujrat where hospital denied accepting Star policies. I would stick to insurance broker rather than directly buying a manufacturer.

Disclosure: views can be biased and may be proven wrong

10 Likes

Exclusive | PB Fintech plans to enter healthcare sector with own hospital chain: Sources

1 Like

IRDAI isn’t too fast?

Inspection made in 2020 & Date of receipt of communication from the authority is 2024

3 Likes

https://www.bseindia.com/xml-data/corpfiling/AttachLive/2017860c-2b3c-4a18-bb63-35eac13bcf5f.pdf

-good growth
-awesome PAT beat YoY and QoQ (ex exceptional items)

3 Likes

Any updates on PB Fintech hospital business, I was expecting something on the concall but nothing discussed.

I was listening to an interview from the management and Yashish said in next 40 to 45 days they will be updating on it.

1 Like

insurance business is a slow growth business in India. particularly in recession frustrated investors will not buy insurance. company’s credit business is also slowing due to tightening of norms by RBI on unsecured loan and POSP business is of thin margin . so company does not deserve 250 PE ratio. everyone is aware about HIGH PE ratio in recession so FIIs selling and stock is crashing . I think we should wait to add or buy freshly this stock. friends what is your opinion ?

This could be win or lose situation for the business?
Experts need opinion!

3 Likes

Interesting Interview. This man has spine, I wish we have more such fearless entrepreneur.

They are planning for HMO - Health Maintenance Organization - type of entity.

  1. As patient you first visit GP.
  2. GP checks you and grant permission to see specialist as per your complain. He has no wasted interest.
  3. You visit the specialist dr / hospital that is part of the HMO network, and your insurance helps pay for it.

But if you go to a hospital outside the HMO network, your insurance won’t pay.

Why Do People Choose HMO?
Cheaper and your GP keeps track of your health.
Disadvantage: Less Freedom or Limited Choices.

PB would start with 400 network Dr / Hospital and will able to provide trustworthy and seamless experience.

Disc: Not invested

3 Likes

From where can I find bifurcation of premium between new business premium and renewal premium. In their investor presentation they have bifurcated it into core online business and new initiatives. Thank you!!

1 Like

I dont think they share it in presentation. mostly available in their concall.

renewal premium varies- but remains in the range of [45-50]% of the total premium. Got this info from sell-side reports.

I don’t think looking at the P/E ratio right now is a good way to analyse Policybaazar. It has recently turned profitable in the last few quarters after years of cash burn and continuous market share. The way their business model works, the P/E will keep decreasing every quarter upto a certain point as they continue increasing the profits (which has a lower base) in a few years. It has a 30% QoQ growth, so hardly a slow growth business. It’s the ever-increasing premium collection YoY and their outlook that makes the stock valued at what it is. Not saying it is fairly valued, but the metrics you mentioned dont really apply in this case.

3 Likes

PB Fintech - management call takeaways

• Management acknowledged a meaningful impact from the proposed commission changes, but believes the market reaction is overstating the long-term damage.

• The strongest statement from the call was that only ~25-33% of the NPV of the non-life business could be impacted, while the life insurance business remains largely unaffected.

• PB intends to recover earnings trajectory by FY2029E, although FY2028E could remain volatile.

• No immediate layoffs or drastic cost cuts are planned; management will focus on balancing growth and profitability rather than pursuing growth at any cost.

• Growth investments will become more selective. Profitability will receive greater attention.

7 Likes

Brokerage models like Motilal Oswal’s—which modeled severe top-line and earnings impact—typically do not fully factor in the nuance that top-tier insurers are already operating close to or below those thresholds. Instead, institutional analysts construct models based on a standardized framework that largely overlooks these granular baselines.

Why Institutional Models Miss This Reality

Blanket Percentage Assumptions: Large brokerages model regulatory drafts by applying flat-rate reductions across entire categories. If a cap reduces the legal maximum ceiling for a sector, institutional models automatically assume that every existing contract currently sitting above that new ceiling will be slashed by the maximum possible delta. They treat distribution economics as a uniform macro equation rather than a mosaic of bespoke, institutional arrangements.

Ignoring the “Sticky Baseline” of Giants: Institutional research desks tend to project worst-case systemic stress to cover themselves legally and analytically when a draft consultation paper drops. They rarely adjust calculations downward for individual partners like SBI Life, LIC, or ICICI Pru unless the insurer explicitly issues formal guidance stating their current commercial take-rates are untouched.

Overlooking Variable Kickbacks vs. Base Pay: Brokerage models often conflate base commissions with total economic payout. Even if a foundational rate (like ICICI Pru’s 18% vs. a 15% cap) looks close on paper, analysts project that the elimination of supplementary volume-linked incentives or promotional marketing support fees will create a broader compound loss than what will actually happen in practice.

3 Likes